We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+30.33%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$1.67B
AUM Growth
+$284M
Cap. Flow
-$40.3M
Cap. Flow %
-2.41%
Top 10 Hldgs %
68.77%
Holding
48
New
7
Increased
25
Reduced
10
Closed
2

Top Buys

Rank Stock Value
1
PRQR icon
ProQR Therapeutics
PRQR
+$39.7M
2
ESTA icon
Establishment Labs
ESTA
+$19.9M
3
VRAY
ViewRay, Inc.
VRAY
+$18.8M
4
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$18.2M
5
RMD icon
ResMed
RMD
+$16.1M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$90.8M
2
RGNX icon
Regenxbio
RGNX
+$44.7M
3
PTCT icon
PTC Therapeutics
PTCT
+$33M
4
SLDB icon
Solid Biosciences
SLDB
+$17.3M
5
ARWR icon
Arrowhead Research
ARWR
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 92.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
26
uniQure
QURE
$3.03B
$15.6M 0.93%
428,980
+19,610
+5% +$729K
SLDB icon
27
Solid Biosciences
SLDB
$849M
$12.4M 0.74%
17,488
-27,563
-61% -$17.3M
PACB icon
28
Pacific Biosciences
PACB
$447M
$12.1M 0.72%
+2,237,607
New +$9.6M
CDNA icon
29
CareDx
CDNA
$2.44B
$10.3M 0.62%
357,766
-406,766
-53% -$7.61M
QTTB icon
30
Q32 Bio
QTTB
$480M
$9.94M 0.6%
24,162
+11,582
+92% +$3.93M
VKTX icon
31
Viking Therapeutics
VKTX
$3.84B
$8.71M 0.52%
+500,000
New +$5.95M
VIVE
32
DELISTED
VIVEVE MED INC
VIVE
$8.44M 0.51%
3,147
+286
+10% +$810K
ECOR icon
33
electroCore
ECOR
$56.2M
$7.2M 0.43%
34,312
+612
+2% +$135K
ODT
34
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$5.62M 0.34%
289,608
+13,240
+5% +$270K
NVTR
35
DELISTED
Nuvectra Corporation Common Stock
NVTR
$5.52M 0.33%
251,329
-131,701
-34% -$2.53M
NVAX icon
36
Novavax
NVAX
$1.26B
$5.21M 0.31%
138,551
+6,334
+5% +$178K
STIM icon
37
Neuronetics
STIM
$160M
$5.05M 0.3%
157,487
-32,513
-17% -$988K
KA
38
DELISTED
Kineta, Inc. Common Stock
KA
$2.72M 0.16%
8,065
+369
+5% +$132K
ARGX icon
39
argenx
ARGX
$52.8B
$2.04M 0.12%
26,853
+1,294
+5% +$115K
VTAK icon
40
Catheter Precision
VTAK
$996K
– –
0
– –
MRKR icon
41
Marker Therapeutics
MRKR
$20.5M
$1.9M 0.11%
20,972
+972
+5% +$83.4K
ELDN icon
42
Eledon Pharmaceuticals
ELDN
$269M
$1.48M 0.09%
17,570
+803
+5% +$82K
ADVM
43
DELISTED
Adverum Biotechnologies
ADVM
$1.12M 0.07%
18,482
+845
+5% +$47.5K
BLCM
44
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$970K 0.06%
15,749
+720
+5% +$48.7K
MOTS
45
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$303K 0.02%
198
– –
PTE
46
DELISTED
PolarityTE, Inc. Common Stock
PTE
– –
-17,067
Closed -$10M
1
2

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $9.92B AUM 21.52% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

RTW Investments's Q3 2018 Portfolio in Review

As of Q3 2018, RTW Investments held 48 positions worth $1.67B, up 20% from $1.39B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

RTW Investments's Q3 2018 filing shows 7 new, 25 increased, 10 reduced and 2 closed positions. Its largest new stake was ProQR Therapeutics: 3,739,406 shares worth $72.4M. The largest sale was Sarepta Therapeutics, an estimated $90.8M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier.

  • RTW Investments's largest Q3 2018 buy was ProQR Therapeutics: 3,739,406 shares worth $72.4M.
  • RTW Investments added most to ViewRay, Inc. in Q3 2018, an estimated $18.8M increase.
  • RTW Investments's biggest Q3 2018 reduction was Sarepta Therapeutics, cutting an estimated $90.8M.
  • RTW Investments fully exited PolarityTE, Inc. Common Stock in Q3 2018, selling an estimated $10M.
  • RTW Investments's ten largest holdings make up 69% of its $1.67B portfolio in Q3 2018.
  • RTW Investments opened 7 new positions and closed 2 in Q3 2018.
  • RTW Investments's portfolio value rose 20% quarter-over-quarter to $1.67B.

Based on RTW Investments's 13F filing for Q3 2018, filed 14 Nov 2018.